Patents by Inventor Kunihiko MORIHIRO

Kunihiko MORIHIRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYCLIC THREONINOL NUCLEIC ACID
    Publication number: 20240009224
    Abstract: The present invention provides a nucleic acid having excellent cell membrane permeability.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 11, 2024
    Applicants: The University of Tokyo, AGC Inc.
    Inventors: Takashi OKAZOE, Kohsuke AIKAWA, Honoka WATANABE, Akimitsu OKAMOTO, Kunihiko MORIHIRO, Taiichi KAGEYAMA
  • NUCLEIC ACID CONTAINING PERFLUOROALKYL GROUP, AND METHOD FOR ITS PRODUCTION
    Publication number: 20220235091
    Abstract: To provide a nucleic acid excellent in cell membrane permeability and a method for its production. A nucleic acid containing a C2-10 perfluoroalkyl group having from 1 to 5 ether-bonding oxygen atoms between carbon atoms; said nucleic acid wherein said perfluoroalkyl group is directly or indirectly bonded to the 5?- or 3?-end of the nucleic acid, or said perfluoroalkyl group is indirectly introduced between two nucleotides; or a nucleic acid medicine comprising, as an active ingredient, a nucleic acid containing a C2-10 perfluoroalkyl group, which may have from 1 to 5 ether-bonding oxygen atoms between carbon atoms.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 28, 2022
    Applicants: AGC Inc., THE UNIVERSITY OF TOKYO
    Inventors: Takashi OKAZOE, Yuichiro ISHIBASHI, Akimitsu OKAMOTO, Kunihiko MORIHIRO, Kohsuke AIKAWA, Honoka WATANABE
  • ANTISENSE OLIGONUCLEIC ACID
    Publication number: 20220170020
    Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.
    Type: Application
    Filed: February 7, 2022
    Publication date: June 2, 2022
    Applicant: Osaka University
    Inventors: Satoshi OBIKA, Reiko WAKI, Takao INOUE, Tokuyuki YOSHIDA, Kunihiko MORIHIRO, Yuya KASAHARA, Atsushi MIKAMI
  • Antisense oligonucleic acid
    Patent number: 11261440
    Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 1, 2022
    Assignee: Osaka University
    Inventors: Satoshi Obika, Reiko Waki, Takao Inoue, Tokuyuki Yoshida, Kunihiko Morihiro, Yuya Kasahara, Atsushi Mikami
  • ANTISENSE OLIGONUCLEIC ACID
    Publication number: 20200056178
    Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 20, 2020
    Applicant: Osaka University
    Inventors: Satoshi OBIKA, Reiko WAKI, Takao INOUE, Tokuyuki YOSHIDA, Kunihiko MORIHIRO, Yuya KASAHARA, Atsushi MIKAMI